Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

31.70 +0.21 (+0.65%)

Streaming Delayed Price Updated: 1:02 PM EDT, May 29, 2026 Add to My Watchlist

Price and Volume

Volume	315,218
Open	31.36
Bid (Size)	31.67 (200)
Ask (Size)	31.73 (100)
Prev. Close	31.49
Today's Range	31.19 - 31.84
52wk Range	25.52 - 40.87
Shares Outstanding	57,031,297
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Harmony Biosciences to Participate in Upcoming Investor Conferences

May 27, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

A Healthcare Fund Just Made Bitgo Its Biggest Bet ↗

May 19, 2026

Bitgo Holdings provides digital asset infrastructure and custody services for institutional clients, supporting secure management at scale.

Via The Motley Fool

Performance

YTD	-15.2%	-15.2%
1 Month	+1.7%	+1.7%
3 Month	+9.1%	+9.1%
6 Month	-10.2%	-10.2%
1 Year	-6.0%	-6.0%

More News

A beaten-down biotech just lost a meaningful backer — should you care? ↗

May 19, 2026

Via The Motley Fool

Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 Revenue Meets Guidance, But EPS Miss and Elevated Spending Weigh on Shares ↗

May 07, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY): A Decent Value Play with Strong Fundamentals ↗

April 28, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Quality at a Discount ↗

March 13, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Reports Q4 2025 Revenue In Line, Earnings Miss Amid Pipeline Investment ↗

February 24, 2026

Via Chartmill

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

May 07, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

April 23, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

April 16, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

April 14, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Compelling Value and Growth Pick ↗

February 20, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗

February 17, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime GARP Investment ↗

February 13, 2026

Via Chartmill

Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit

April 07, 2026

Via Finterra

Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’

April 06, 2026

Via MarketMinute

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar

April 06, 2026

Via MarketMinute

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

April 02, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

March 31, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in Upcoming Investor Conferences

March 04, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences (HRMY) Earnings Transcript ↗

February 24, 2026

Via The Motley Fool

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

February 24, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

HRMY Stock Rises On Fresh FDA Approval For Wakix Tablets In Children But Wall Street Eyes Further Rally ↗

February 17, 2026

Via Stocktwits

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

February 17, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

February 10, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Frequently Asked Questions

Is Harmony Biosciences Holdings, Inc. - Common Stock publicly traded?

Yes, Harmony Biosciences Holdings, Inc. - Common Stock is publicly traded.

What exchange does Harmony Biosciences Holdings, Inc. - Common Stock trade on?

Harmony Biosciences Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock?

The ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock is HRMY on the Nasdaq Stock Market

What is the current price of Harmony Biosciences Holdings, Inc. - Common Stock?

The current price of Harmony Biosciences Holdings, Inc. - Common Stock is 31.70

When was Harmony Biosciences Holdings, Inc. - Common Stock last traded?

The last trade of Harmony Biosciences Holdings, Inc. - Common Stock was at 05/29/26 01:02 PM ET

What is the market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock?

The market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock is 1.81B

How many shares of Harmony Biosciences Holdings, Inc. - Common Stock are outstanding?

Harmony Biosciences Holdings, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.